Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) were up 5.8% during trading on Friday . The stock traded as high as $3.32 and last traded at $3.28, with a volume of 142,948 shares changing hands. The stock had previously closed at $3.10.

Separately, Maxim Group increased their price target on shares of Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, March 29th.

The firm’s market cap is $49.54 million. The stock’s 50-day moving average price is $4.73 and its 200 day moving average price is $5.73.

In other Adamis Pharmaceuticals Corp. news, SVP David J. Marguglio sold 4,000 shares of Adamis Pharmaceuticals Corp. stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $8.08, for a total value of $32,320.00. Following the completion of the sale, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David J. Marguglio sold 4,860 shares of Adamis Pharmaceuticals Corp. stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $9.17, for a total transaction of $44,566.20. Following the completion of the sale, the senior vice president now owns 112,227 shares of the company’s stock, valued at approximately $1,029,121.59. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.